Trial Profile
A Phase 1, Open-label, Parallel-group Study to Assess The Effect Of CYP3A5 Genotype on the Pharmacokinetics of Maraviroc and CYP3A5-derived Metabolites With and Without Darunavir/Cobicistat In African-American and Caucasian Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Maraviroc (Primary) ; Cobicistat/darunavir
- Indications HIV-1 infections
- Focus Pharmacogenomic; Pharmacokinetics
- Sponsors ViiV Healthcare
- 07 Sep 2018 Results published in the Journal of Clinical Pharmacology
- 16 Feb 2017 Results presented at the 24th Conference on Retroviruses and Opportunistic Infections
- 11 Apr 2016 Status changed from recruiting to completed.